within Pharmacolibrary.Drugs.ATC.N;

model N03AA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.95,
    Cl             = 6.666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 0.1,
    adminCount     = 1,
    Vd             = 0.0008,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Methylphenobarbital is a barbiturate anticonvulsant, structurally related to phenobarbital, historically used in the treatment of epilepsy and seizure disorders. Its use has greatly declined and it is not widely approved or available in many countries today due to the availability of safer alternatives.</p><h4>Pharmacokinetics</h4><p>No specific pharmacokinetic data in humans are available from existing publications. Parameters estimated by analogy to phenobarbital and general barbiturate properties; assumed for healthy adults after oral administration.</p><h4>References</h4><ol><li>W H Lim, W D Hooper,Stereoselective metabolism and pharmacokinetics of racemic methylphenobarbital in humans.,Drug metabolism and disposition: the biological fate of chemicals,1989<a href='https://pubmed.ncbi.nlm.nih.gov/2565213/'>https://pubmed.ncbi.nlm.nih.gov/2565213/</a></li><li>W D Hooper, H E Kunze, M J Eadie,Pharmacokinetics and bioavailability of methylphenobarbital in man.,Therapeutic drug monitoring,1981<a href='https://pubmed.ncbi.nlm.nih.gov/7233487/'>https://pubmed.ncbi.nlm.nih.gov/7233487/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N03AA01;
